Last reviewed · How we verify

Savara Inc. — Portfolio Competitive Intelligence Brief

Savara Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Vancomycin inhalation powder Vancomycin inhalation powder phase 3 glycopeptide antibiotic cell wall precursors Infectious Disease
Molgramostim Open-label Molgramostim Open-label phase 3 Cytokine; GM-CSF receptor agonist GM-CSF receptor (CD116/CD131) Immunology; Rare/Orphan Diseases

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Armata Pharmaceuticals, Inc. · 1 shared drug class
  2. Astellas Pharma Europe B.V. · 1 shared drug class
  3. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 shared drug class
  4. Krishnadevaraya College of Dental Sciences & Hospital · 1 shared drug class
  5. Kurobe LLC · 1 shared drug class
  6. Major Extremity Trauma Research Consortium · 1 shared drug class
  7. NovaBay Pharmaceuticals, Inc. · 1 shared drug class
  8. Riyadh Colleges of Dentistry and Pharmacy · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Savara Inc.:

Cite this brief

Drug Landscape (2026). Savara Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/savara-inc. Accessed 2026-06-10.

Related